Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Joseph Eid is EVP, R&D; Chief Medical Office at Geron. OQRO lists 1 transaction filed with the SEC under this name, the latest on Feb 19, 2026, each linked to the official Form 4.
EVP, R&D; Chief Medical Office
Disclosures on record
1
Companies involved
1
GeronGERN
Feb 17, 20262.22Mdisclosed Feb 19
DetailsOfficial recordJoseph Eid has no open-market purchase on record since 2020. Sales in 2 of the 7 years since 2020.
Joseph Eid reported 0 open-market purchases and 2 sales since 2020; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2021 | — | $73K1×1 trade |
| 2020 | — | $341K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Joseph Eid has no open-market purchase on record since 2020. Sales in 2 of the 7 years since 2020.
In SEC filings since 2020: no open-market purchase is on record; the latest open-market sale is from 2021.
Bristol Myers Squibb (BMY), from 2020 to 2021: 0 purchases and 2 sales.
Joseph Eid reported 0 open-market purchases and 2 sales here, 2020 to 2021.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.